AzTrials
AzTrials

Alcohol-Related DisordersMAIN-ARTNCT04473482

Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial

A study testing Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool in people with Alcohol-Related Disorders and Liver Diseases, run by University of Michigan at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to determine if providing participants with alcohol-related liver disease with tailored alcohol use treatment options is feasible and acceptable in order to increase their engagement with treatment and reduce alcohol use. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Alcohol-Related Disorders, Liver Diseases
What is being tested?
Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteUnited States
Study dates
23 Sep 2020to 30 Jun 2022
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Enrolled at University of Michigan general hepatology clinics or inpatient wards
  • Documented diagnosis of alcohol-associated cirrhosis or alcoholic hepatitis or alcohol-related liver disease of any stage
  • Drinking of any amount of alcohol within the 6 months prior to recruitment
  • No alcohol use treatment within the past 1 month
  • Access to a phone for purposes of follow-up

Who cannot join

  • Active alcohol use treatment
  • Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation.
  • Is enrolled in the multidisciplinary alcohol-related liver disease clinic at Michigan Medicine

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The University of Michigan

    Ann Arbor, Michigan, 48109

Other trials in United States

About this study

The purpose of the study is to determine if providing participants with alcohol-related liver disease with tailored alcohol use treatment options is feasible and acceptable in order to increase their engagement with treatment and reduce alcohol use. This is an important area to study to help create ways to increase participants' knowledge about different treatment options as well as increase likelihood of seeking and participating in alcohol use disorder treatments.

Being tested
Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool
Medical subject headings
Alcohol-Related Disorders, Liver Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment toolBehavioural

    The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.

Study groups in NCT04473482
Study groupRoleWhat they receive
MAIN-ART Behavior ToolExperimentalThe Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Tool (MAIN-ART) behavioral intervention is an online web application with two modules: misconception correction and tailored, preference-sensitive alcohol use disorder (AUD) treatment matching.
Receives: Behavioral: Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool
Routine careNo interventionPatients randomized to usual care will receive a pamphlet for alcohol treatment referral to the University of Michigan Addiction Treatment Services, but will receive no further education from the research team.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility of MAIN-ART Tool as Measured by Recruitment Rates

    Feasibility of administration of the MAIN-ART tool will be determined by recruitment rates and retention rates (as measured at 6 months after recruitment). Study recruitment started on 23 September, 2020 and concluded on 10 January 2022. The results reflect the number and percent of those patients who were approached, were determined to be eligible, and were consented.

    Measured: Up to 6 months

  2. Feasibility of MAIN-ART Tool as Measured by Retention Rates

    Feasibility of administration of the MAIN-ART tool will be determined by recruitment rates and retention rates (as measured at 6 months after recruitment). Retention rate is shown by the number of participants who continued in the study for 6 months, and the percentage that it represents compared to those who began it but did not follow through to the end of the study (6 months).

    Measured: Up to 6 months

  3. Acceptability of the MAIN-ART Tool as Measured by Post-intervention Surveys

    On the day the participants engage with the MAIN-ART tool, acceptability will be determined by patient-level surveys. The System usability Survey (SUS) consists of 10 questions ranging from 1 (strongly disagree) to 5 (strongly agree). A scoring algorithm which produces a range from 0 to 100 was used. Current literature suggests that a score above 68 for mean SUS is considered "above average." By "intervention," this measure means interaction with the MAIN-ART tool, which occurs only at the participant's initial visit.

    Measured: Up to 1 hour

Secondary outcomes (2)
  1. Alcohol Use Frequency as Measured by the Alcohol Timeline Follow-back (TLFB) Interview

    Alcohol use will be defined according to World Health Organization (WHO) risk drinking level. WHO drinking risk levels were derived from patient reports of the number of standard drinks (defined as 0.6 ounces of absolute alcohol) consumed, which were converted to grams of pure alcohol (0.6 ounces = 14 grams). Ranging from abstinence (0 grams) to very high risk (101+ males / 61+ females grams).

    Measured: Baseline and 6 months

  2. Alcohol Treatment Engagement as Measured by Number of Participants Who Engaged in Any Alcohol Cessation or Reduction Visit as Measured by Self-report.

    Alcohol treatment engagement will be defined as at least one visit with formal, external assistance in alcohol cessation or reduction including inpatient rehabilitation services, out patient alcohol cessation programs, engagement in therapy of any kind tailored for alcohol cessation, and engagement in any group therapy or support groups for alcohol cessation including alcoholics anonymous, 12 step facilitation and etc.

    Measured: Up to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jul 2020
  2. Study start23 Sep 2020
  3. Primary completion30 Jun 2022
  4. Study completion30 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04473482
Sponsor's protocol ID
HUM00174946
Other IDs
5K23AA026333-02
Acronym
MAIN-ART
Status last verified
Aug 2023
First submitted
13 Jul 2020
Last updated
30 Aug 2023
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Mellinger JL, Medley S, Kidwell KM, Asefah H, Winder GS, Fernandez AC, Lok ASF, Blow F. Improving alcohol treatment engagement using integrated behavioral interventions in alcohol-associated liver disease: A randomized pilot trial. Hepatol Commun. 2023 Sep 15;7(10):e0181. doi: 10.1097/HC9.0000000000000181. eCollection 2023 Oct 1.

    PubMed 37708435

Questions about this trial

What is this clinical trial studying?

A study testing Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool in people with Alcohol-Related Disorders and Liver Diseases, run by University of Michigan at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Aug 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of MAIN-ART Tool as Measured by Recruitment Rates (time frame: Up to 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04473482, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in